Kenny Walter

Liesbeth Reneman, MD, PhD New research suggests a common ADHD medication affects the brain’s signal-carrying white matter in children, but not in adults suffering from the disorder. Study senior author Liesbeth Reneman, MD, PhD, from the Department of Radiology and Nuclear Medicine at the Academic Medical Center, University of Amsterdam, led a team in discovering that methylphenidate (MPH), also sold as Ritalin and Concerta, affects the development of the area of the brain associated with le…

Could addressing insulin resistance in patients reverse the course of diabetes while reducing the risk of comorbid cardiovascular events and chronic kidney disease? New research presented during the 18th World Congress of Insulin Resistance Diabetes & Cardiovascular (WCIRDC) Online CME Conference presented by the Metabolic Institute of America (TMIOA), shows the particular role of diacylglycerol and acetyl-CoAin might play in insulin resistance. In an interview with HCPLive®, Gerald Shulma…

Mirikizumab continues to outperform placebo in data from a pair of new trials evaluating the drug in patients with ulcerative colitis.1 A team, led by Geert D’Haens, MD, PhD, compared mirikizumab to placebo in both an induction trial and a maintenance trial involving patients with moderately to severely active ulcerative colitis. Mirikizumab In phase 2 trials, mirikizumab, which is a p19-directed antibody against interleukin-23, has shown promise in treating patients with ulcerative colit…

Pediatric sleep conditions remain understudied.

RBX2660 was the first ever live microbiota therapeutic to gain approval from the FDA for rCDI.

Guselkumab is currently being evaluated as a treatment for both ulcerative colitis and Crohn’s disease.

Recent studies have indicated that using adenoma per colonoscopy as a metric could help better forecast the risk of colon cancer.

The risk of developing high grade dysplasia or esophageal adenocarcinoma was higher in patients with Barrett’s esophagus with immunosuppressant medication use.

There is some concern that the prevalence of diseases like NASH and NAFLD may increase in the coming years.

RBX2660 and Vowst are now both approved for the prevention of recurrent C. difficile infections.

Patients in long-remission also presented with fecal bacterial composition that was similar to what was found in the healthy control group and there was a positive correlation between Akkermansia muciniphila abundance and time in remission.

Liver stiffness, body weight, and metabolic risk factors were significantly and comparably reduced in both groups.

The prevalence of CDI in southern China was 11.0% and 13.6% in northern China.

The overall survival after adjusting for tumor stage showed tumor adipose feature was independently prognostic as both a binary feature and as a semiquantitative categorical feature.

Clostridium difficile and Clostridium perfringens were found in 83% of newborns nursed by formula milk in the second week of life, but all infants by the end of the third week of life.

Recent data during ECCO 23 show ustekinumab results in higher rates of clinical remission and clinical response in patients with inflammatory bowel disease.

Neutropenia, male gender, high serum creatinine, and albumin were all associated with fatal outcomes.

There was a 0.9% increase in the first dispensation of infliximab, either the biosimilar or originator during the first year of follow-up, as well as a 16.2% increase in infliximab dose escalation, a 2.4% decrease in the dispensation of antibiotics, and a 2.6% decrease in the new use of prednisone.

A new analysis show augmenting to aripiprazole results in higher levels of remission for older adults with treatment resistant depression (TRD) compared to augmenting or switching to bupropion.1 A team, led by Eric J. Lenze, MD, Washington University School of Medicine in St. Louis, compared several treatment options for patients aged at least 60 years with treatment resistant depression. In the past, research has seldomly focused on the benefits and risks of augmenting or switching antide…

The results from a Bayesian reinforcement learning model showed the antidepressant placebo trial-wise expectancies were updated by composite learning signals multiplexing sensory evidence and trial-wise mood.